Letrozole
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Severe and Recurrent Endometriosis
Conditions
Severe and Recurrent Endometriosis
Trial Timeline
Oct 1, 2002 → Jun 1, 2006
NCT ID
NCT00240942About Letrozole
Letrozole is a phase 2 stage product being developed by Novartis for Severe and Recurrent Endometriosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00240942. Target conditions include Severe and Recurrent Endometriosis.
What happened to similar drugs?
20 of 20 similar drugs in Severe and Recurrent Endometriosis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01908556 | Approved | UNKNOWN |
| NCT00856050 | Phase 2 | Completed |
| NCT00688909 | Approved | Completed |
| NCT00549822 | Phase 2 | Terminated |
| NCT00414076 | Phase 2 | Terminated |
| NCT00382070 | Phase 3 | Active |
| NCT00332852 | Phase 3 | Completed |
| NCT00330317 | Phase 3 | Completed |
| NCT00329940 | Phase 3 | Completed |
| NCT00171808 | Phase 2 | Completed |
| NCT00237133 | Approved | Completed |
| NCT00237224 | Approved | Completed |
| NCT00291135 | Phase 2 | Completed |
| NCT00240942 | Phase 2 | Completed |
| NCT00333047 | Phase 2/3 | Completed |
| NCT00241046 | Approved | Terminated |
| NCT00014638 | Approved | Completed |
| NCT00535418 | Phase 2/3 | Completed |
| NCT00333086 | Phase 2 | Completed |
Competing Products
20 competing products in Severe and Recurrent Endometriosis